CA2485472A1 - Secretagogues a hormone de croissance et leurs utilisations - Google Patents
Secretagogues a hormone de croissance et leurs utilisations Download PDFInfo
- Publication number
- CA2485472A1 CA2485472A1 CA002485472A CA2485472A CA2485472A1 CA 2485472 A1 CA2485472 A1 CA 2485472A1 CA 002485472 A CA002485472 A CA 002485472A CA 2485472 A CA2485472 A CA 2485472A CA 2485472 A1 CA2485472 A1 CA 2485472A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- composition
- subject
- secretagogue
- ch2ch3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000580 secretagogue effect Effects 0.000 title claims abstract 41
- 239000000203 mixture Substances 0.000 claims abstract 98
- 150000002632 lipids Chemical class 0.000 claims abstract 15
- 230000001925 catabolic effect Effects 0.000 claims abstract 13
- 230000003920 cognitive function Effects 0.000 claims abstract 8
- 230000002503 metabolic effect Effects 0.000 claims abstract 8
- 230000003247 decreasing effect Effects 0.000 claims abstract 5
- 230000002950 deficient Effects 0.000 claims abstract 5
- 230000036737 immune function Effects 0.000 claims abstract 5
- 230000011164 ossification Effects 0.000 claims abstract 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract 4
- 102000018997 Growth Hormone Human genes 0.000 claims 60
- 108010051696 Growth Hormone Proteins 0.000 claims 60
- 239000000122 growth hormone Substances 0.000 claims 60
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 24
- 150000001413 amino acids Chemical group 0.000 claims 21
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 18
- 239000003937 drug carrier Substances 0.000 claims 18
- 208000006132 lipodystrophy Diseases 0.000 claims 18
- 230000004075 alteration Effects 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 235000012000 cholesterol Nutrition 0.000 claims 12
- 230000003187 abdominal effect Effects 0.000 claims 10
- 238000007920 subcutaneous administration Methods 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 210000001519 tissue Anatomy 0.000 claims 7
- 208000032928 Dyslipidaemia Diseases 0.000 claims 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 6
- 206010062315 Lipohypertrophy Diseases 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- 210000004003 subcutaneous fat Anatomy 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010020100 Hip fracture Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 208000029725 Metabolic bone disease Diseases 0.000 claims 3
- 206010049088 Osteopenia Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 230000000840 anti-viral effect Effects 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- WAOQOSHNKJFOTO-BMGKTWPMSA-N hex-hgrf Chemical compound C([C@H](NC(=O)C/C=C/CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 WAOQOSHNKJFOTO-BMGKTWPMSA-N 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 210000001596 intra-abdominal fat Anatomy 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 230000003387 muscular Effects 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 239000003488 releasing hormone Substances 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 230000009278 visceral effect Effects 0.000 claims 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2485472A CA2485472C (fr) | 2004-10-20 | 2004-10-20 | Secretagogues a hormone de croissance et leurs utilisations |
| EP05797145A EP1812048A4 (fr) | 2004-10-20 | 2005-10-20 | Secretagogues de la gh et utilisations de ceux-ci |
| MX2007004682A MX2007004682A (es) | 2004-10-20 | 2005-10-20 | Secretagogos de gh y usos de los mismos. |
| JP2007537087A JP2008516994A (ja) | 2004-10-20 | 2005-10-20 | 成長ホルモン分泌促進因子およびその使用 |
| PCT/CA2005/001611 WO2006042408A1 (fr) | 2004-10-20 | 2005-10-20 | Secretagogues de la gh et utilisations de ceux-ci |
| AU2005297366A AU2005297366B2 (en) | 2004-10-20 | 2005-10-20 | GH secretagogues and uses thereof |
| BRPI0516935-6A BRPI0516935A (pt) | 2004-10-20 | 2005-10-20 | secretagogos de gh e usos dos mesmos |
| CN200580043640XA CN101084009B (zh) | 2003-05-29 | 2005-10-20 | Gh促分泌素及其用途 |
| KR1020077011178A KR101228229B1 (ko) | 2004-10-20 | 2005-10-20 | 성장 호르몬 분비 촉진물질 및 그의 용도 |
| NO20072136A NO20072136L (no) | 2004-10-20 | 2007-04-24 | Substans som fremmer GH-sekresjon og anvendelse derav |
| HK08106222.9A HK1115803A1 (en) | 2004-10-20 | 2008-06-04 | Gh secretagogues and uses thereof gh |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2485472A CA2485472C (fr) | 2004-10-20 | 2004-10-20 | Secretagogues a hormone de croissance et leurs utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2485472A1 true CA2485472A1 (fr) | 2006-04-20 |
| CA2485472C CA2485472C (fr) | 2011-09-27 |
Family
ID=36242546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2485472A Active CA2485472C (fr) | 2003-05-29 | 2004-10-20 | Secretagogues a hormone de croissance et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| BR (1) | BRPI0516935A (fr) |
| CA (1) | CA2485472C (fr) |
| HK (1) | HK1115803A1 (fr) |
| MX (1) | MX2007004682A (fr) |
-
2004
- 2004-10-20 CA CA2485472A patent/CA2485472C/fr active Active
-
2005
- 2005-10-20 MX MX2007004682A patent/MX2007004682A/es active IP Right Grant
- 2005-10-20 BR BRPI0516935-6A patent/BRPI0516935A/pt not_active Application Discontinuation
-
2008
- 2008-06-04 HK HK08106222.9A patent/HK1115803A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2485472C (fr) | 2011-09-27 |
| MX2007004682A (es) | 2007-07-17 |
| BRPI0516935A (pt) | 2008-09-23 |
| HK1115803A1 (en) | 2008-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230120030A1 (en) | Long-Acting Adrenomedullin Derivatives | |
| EP1455814B1 (fr) | Compositions pharmaceutiques comprenant de la ghreline non acylee pour leur utilisation dans le traitement de la resistance a l'insuline | |
| USRE40850E1 (en) | Analogs of parathyroid hormone | |
| JP2902115B2 (ja) | 新規アミリン作動薬ペプチドおよびその使用 | |
| EP1716172B1 (fr) | Peptides de la famille amyline et procedes de production et d'utilisation desdits peptides | |
| ES2359031T3 (es) | Composición farmacéutica que comprende un péptido de exendina-4. | |
| JP3576170B2 (ja) | 生物学的活性が増加したキメラ脂肪体プロｇｒｆ類似体 | |
| KR100699422B1 (ko) | 부갑상선 호르몬의 동족체 | |
| US8076281B2 (en) | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment | |
| EP2347762A1 (fr) | Exendin pour le traitement du diabète et la réduction du poids | |
| KR101228229B1 (ko) | 성장 호르몬 분비 촉진물질 및 그의 용도 | |
| TWI353250B (en) | Glp-1 pharmaceutical compositions | |
| WO1996032126A1 (fr) | Analogues du facteur liberant l'hormone de croissance | |
| EP0969016A2 (fr) | Derivés d'insulinotropine et de peptide analogue au glucagon | |
| CA2527039C (fr) | Compositions d'analogues grf et leur utilisation | |
| JP2013518090A5 (fr) | ||
| JP4726797B2 (ja) | 消耗症に罹患している患者の治療における成長ホルモン放出因子類似体の使用 | |
| BG65137B1 (bg) | Антагонистични аналози на gh-rh инхибиращи igf-i и -ii | |
| WO2015180634A1 (fr) | Analogue de polypeptide d'entérocrinine à action prolongée pour le traitement du diabète de type 2 et ses utilisations | |
| CA2470235C (fr) | Compositions pharmaceutiques comprenant de la ghreline non acylee et utilisations therapeutiques de ces compositions | |
| CA2485472A1 (fr) | Secretagogues a hormone de croissance et leurs utilisations | |
| CN1145808A (zh) | 用于成年人的人生长激素制剂 | |
| US20060052289A1 (en) | Use of somatostatin analogs in sleep apnea | |
| Schally et al. | Agonistic Analogs of Growth Hormone-Releasing Hormone: Endocrine and Growth Studies: Growth | |
| US6949513B2 (en) | Polypeptides of covalently linked synthetic bioactive peptide analog(s) for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |